Περίληψη:
BACKGROUND: Malignant mixed Mullerian tumours (MMMTs) of the uterus and
adnexa represent aggressive gynaecologic malignancies with a high rate
of loco-regional and distant failure. For that reason, we evaluated the
paclitaxel-ifosfamide-carboplatin (TICb) combination in patients with
advanced MMMTs.
METHODS: Female patients with advanced MMMTs, WHO-PS 0-2, no prior
chemotherapy for systemic disease, unimpaired haemopoietic and organ
function were eligible. Chemotherapy was administered at the following
doses; paclitaxel: 175 mg m(-2) on day 1, ifosfamide: 2.0 g m(-2)
day(-1) - days 1 and 2, and carboplatin at a target area under the curve
5 on day 2, with prophylactic G-CSF from day 3.
RESULTS: Forty patients of a median age 61 (45-72) years, performance
status 0-2 with advanced MMMTs of the uterus (n = 34), tubes (n = 2) or
ovary (n = 4) have entered and all were evaluable for response and
toxicity. Responses were as follows: 27 out of 40 (67.5%) evaluable
patients responded, with 11 complete responses and 16 partial responses,
while 10 had stable disease, and 3 developed progressive disease. The
median response duration was 9 months (range, 4-40 months), median
progression-free survival 13 months (range, 3-42 months), while median
overall survival 18 months (range, 4-48 months). Grade 3/4 neutropenia
was recorded in 22 out of 40 (55%) - with 13 developing grade 4 (<= 7
days) and 7 out of 40 (17.5%) of patients at least one episode of
febrile neutropenia.
CONCLUSION: In this study, it appears that the TICb combination, yielded
important activity with manageable toxicity in females with advanced
MMMTs warranting further randomised comparison with current standard
regimens. British Journal of Cancer (2011) 105, 897-902.
doi:10.1038/bjc.2011.316 www.bjcancer.com Published online 16 August
2011 (C) 2011 Cancer Research UK
Συγγραφείς:
Kosmas, C.
Vorgias, G.
Tsakonas, G.
Politis, P. and
Daladimos, T.
Panagiotidi, E.
Papachrysanthou, T.
Moschovis,
D.
Kalinoglou, N.
Tsavaris, N.
Karabelis, A.
Mylonakis,
N.
